Search

everythinglearnresearchcommunity

for

Search:↓

Latanoprost at 0.1% concentration is used to increase hair counts, often mixed with Minoxidil and Finasteride. Users report noticeable results in about 3 months.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.

The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.

The conversation is about OP's hair regrowth progress using dutasteride, 5% minoxidil, dermarolling, ketoconazole, adapalene, and vitamin D. Some users doubt the progress, attributing it to longer hair and lighting, while others congratulate OP on the visible improvement.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

A user applied Minoxidil foam to their face to grow a beard and experienced increased hair density and darker hair as unintended benefits, despite initially using it for diffuse thinning on the scalp. Another person suggested that the user's heart rate increase might indicate a high conversion rate of Minoxidil to its active form, similar to taking oral Minoxidil.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.

Switching from 2% liquid minoxidil to 5% foam minoxidil reduced scalp irritation but increased eyebrow flakiness and thinning. The user speculates that propylene glycol in the liquid formulation might have been protecting against seborrheic dermatitis while causing contact dermatitis.

The conversation discusses hair regrowth after a health condition, with the appearance of white substance on the scalp. Suggestions include it being sebum or White Piedra, with a recommendation to try Nizoral.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.

Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

User taking 1mg finasteride daily for 2 years, wants to block more scalp DHT. Seeks reference for additional topical DHT blockers like alfatradiol and fluridil.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

The user has been using Minoxidil for 10 months, along with derma rolling and taking vitamin D. They plan to try g20026 or pyril once available.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

The user seeks alternatives to Propylene Glycol (PG) for delivering topical finasteride due to scalp irritation. They consider using Propanediol 1,3 and ask for other suggestions.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

A user is considering a hair transplant in a "mohawk" pattern with scalp micropigmentation (SMP) on the sides and back, questioning its feasibility and appearance. Others discuss donor region quality, potential scarring, and alternative treatments like dutasteride and RU58841.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.